July 09, 2014
1 min read

Low vitamin D increased risk for advanced liver fibrosis, decreased SVR rate among patients with HCV

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Risks for advanced liver fibrosis and odds for achieving sustained virologic response were affected by vitamin D levels in patients with hepatitis C virus who were taking pegylated interferon-alfa with ribavirin in a recent study.

Researchers conducted a meta-analysis of 14 included studies published from 2011 to 2014 after a literature search of PubMed, Scopus, Lilacs and Cochrane Library databases. Seven studies focused on vitamin D and advanced liver fibrosis (ALF) in treatment-naive patients with chronic hepatitis C virus (HCV; n=1,083), and 11 centered on vitamin D and its relationship with patients with chronic HCV who achieved sustained virologic response (SVR) with pegylated interferon-alfa plus ribavirin (n=2,672). Four studies were examined in both analyses.

Data indicated that almost 70% of all patients had 25-hydroxyvitamin D (25[OH]D) levels that were considered suboptimal (<20 ng/mL or <30 ng/mL), and almost 50% of the patients displayed deficient levels of 25(OH)D (<10 ng/mL or <20 ng/mL). Greater suboptimal levels of vitamin D were observed in 82.7% of patients coinfected with HCV and HIV vs. 66.2% among patients with HCV.

Vitamin D status was associated with ALF, including cut-offs of 10 ng/mL (OR=2.37; 95% CI, 1.20-4.72) and 30 ng/mL (OR=2.22; 95% CI, 1.24-3.97). In the SVR studies, pooled ORs showed an association between cut-offs of 20 ng/mL and SVR for patients when a specific HCV genotype was not stratified (OR=0.53; 95% CI, 0.31-0.91). Heterogeneity also was observed across the SVR studies (P<.001).

“This meta-analysis shows that a low vitamin D status in CHC patients is associated with a higher likelihood of having ALF and lower odds of achieving SVR, suggesting the utility of vitamin D screening in HCV-infected patients,” the researchers wrote.

Disclosure: The researchers report no relevant financial disclosures.